Renaissance Technologies's FOLD Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 1.21 M shares of Amicus Therapeutics, Inc. (FOLD) worth $17.25 M, representing 0.03% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in FOLD, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 1.34 M shares. Largest reduction occurred in Q4 2019, reducing 1.34 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Amicus Therapeutics (FOLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amicus Therapeutics (FOLD) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +173,644 | Add 0.00% | 173,644 | $2.33 |
| Q3 2013 | +128,956 | Add 74.26% | 302,600 | $2.32 |
| Q4 2013 | +96,801 | Add 31.99% | 399,401 | $2.35 |
| Q1 2014 | -278,401 | Reduce 69.70% | 121,000 | $2.07 |
| Q2 2014 | -121,000 | Sold Out | 0 | $0.00 |
| Q3 2014 | +130,400 | New Buy | 130,400 | $5.95 |
| Q4 2014 | +378,300 | Add 290.11% | 508,700 | $8.32 |
| Q1 2015 | -508,700 | Sold Out | 0 | $0.00 |
| Q3 2016 | +196,400 | New Buy | 196,400 | $7.40 |
| Q4 2016 | -196,400 | Sold Out | 0 | $0.00 |
| Q2 2019 | +253,800 | New Buy | 253,800 | $12.48 |
| Q3 2019 | +1.22 M | Add 479.51% | 1.47 M | $8.02 |
| Q4 2019 | -1.34 M | Reduce 91.17% | 129,854 | $9.74 |
| Q1 2020 | -129,854 | Sold Out | 0 | $0.00 |
| Q3 2022 | +284,800 | New Buy | 284,800 | $10.44 |
| Q4 2022 | -284,800 | Sold Out | 0 | $0.00 |
| Q1 2023 | +389,000 | New Buy | 389,000 | $0.01 |
| Q2 2023 | -389,000 | Sold Out | 0 | $0.00 |
| Q3 2023 | +148,400 | New Buy | 148,400 | $12.16 |
| Q4 2023 | -71,000 | Reduce 47.84% | 77,400 | $14.19 |
| Q1 2024 | +878,800 | Add 1135.40% | 956,200 | $11.78 |
| Q2 2024 | -324,176 | Reduce 33.90% | 632,024 | $9.92 |
| Q3 2024 | +137,276 | Add 21.72% | 769,300 | $10.68 |
| Q4 2024 | +1.34 M | Add 174.10% | 2.11 M | $9.42 |
| Q1 2025 | -546,623 | Reduce 25.92% | 1.56 M | $8.16 |
| Q2 2025 | +451,600 | Add 28.91% | 2.01 M | $5.73 |
| Q3 2025 | -70,422 | Reduce 3.50% | 1.94 M | $7.88 |
| Q4 2025 | -731,478 | Reduce 37.64% | 1.21 M | $14.24 |
Renaissance Technologies's Amicus Therapeutics Investment FAQs
Renaissance Technologies first purchased Amicus Therapeutics, Inc. (FOLD) in Q2 2013, acquiring 173,644 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Amicus Therapeutics, Inc. (FOLD) for 28 quarters since Q2 2013.
Renaissance Technologies's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q4 2024, adding 2,108,616 shares worth $19.86 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 1,211,693 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $17.25 M.
As of the Q4 2025 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.03% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Amicus Therapeutics, Inc. (FOLD) was 2,108,616 shares, as reported at the end of Q4 2024.